Search
Now showing items 31-38 of 38
Catechol-O-methyltransferase activity does not influence emotional processing in men
(2022-04)
Background: Catechol-O-methyltransferase (COMT) regulates cortical dopaminergic transmission and prefrontal-dependent cognitive function. However, its role in other cognitive processes, including emotional processing, is ...
Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model
(2022-02)
Donepezil, galantamine, rivastigmine and memantine are potentially effective interventions for cognitive impairment in dementia, but the use of these drugs has not been personalised to individual patients yet. We examined ...
Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil
(2022-02)
The association between early improvement and subsequent change in cognition is unexamined in antidementia clinical trials. We aimed to examine the consequences of early-response to antidementia medication in Alzheimer's ...
Effect of glucose and sucrose on cognition in healthy humans: a systematic review and meta-analysis of interventional studies
(2020-06)
Context: Evidence suggests that plasma glucose levels may influence cognitive performance, but this has not been systematically reviewed and quantified. Objective: The aim of this review was to investigate the potential ...
Validation of the UK English Oxford Cognitive Screen-Plus in Sub-Acute and Chronic Stroke Survivors.
(2022-06)
Stroke survivors are routinely screened for cognitive impairment with tools that often fail to detect subtle impairments. The Oxford Cognitive Screen-Plus (OCS-Plus) is a brief tablet-based screen designed to detect subtle ...
Déjà-vu? Neural and behavioural effects of the 5-HT 4 receptor agonist, prucalopride, in a hippocampal-dependent memory task
(2021-10)
Cognitive deficits commonly accompany psychiatric disorders but are often underrecognised, and difficult to treat. The 5-HT4 receptor is a promising potential treatment target for cognitive impairment because in animal ...
Patient and stakeholder engagement on the role that Social Prescribing might play in supporting the health and wellbeing of people diagnosed with Mild Cognitive Impairment
(2022-11)
There is no standardised clinical care for people with mild cognitive impairment (MCI) postdiagnosis. Social prescribing could potentially address this gap, as it enables people to
access a range of non-clinical organisations ...
Translating the promise of 5HT4 receptor agonists for the treatment of depression
(2020-02)
Animal experimental studies suggest that 5-HT4 receptor activation holds promise as a novel
target for the treatment of depression and cognitive impairment. 5-HT4 receptors are postsynaptic
receptors that are located in ...